American Medical Journal 3 (2): 220-227, 2012 ISSN 1949-0070 © 2012 Science Publications

Recent Clinical Advancement of the Effects of Parathyroid Analogues on Fracture Healing in Humans: A Review of Literature

¹Wen Wei Gerard Ee, ²Wen Liang Joel Lau, ²Harish Sivasubramanian and ¹Diarmuid Murphy ¹Department of Orthopaedics, Faculty of University Orthopaedics, National University Hospital (S) Pte Ltd, Hand and Reconsstructive Microsurgery Cluster, Lower Kent Ridge Road Singapore 119074, Singapore ²Department of Undergraduate Studies, Faculty of Yong Loo Lin School of Medicine, National University Singapore, Lower Kent Ridge Road Singapore 119074, Singapore

Abstract: Problem statement: Numerous animal studies have shown that administration of Parathyroid Hormone (PTH) or a related analogue promotes callus formation and bone union. However, there has yet to be sufficient evidence in human subjects to justify the use of PTH or related analogues in promoting fracture healing. The purpose of this paper is to (1) review all literature involving the use of PTH analogues in humans (2) compare the clinical efficacy of PTH analogues to conventional management of fracture healing and (3) evaluate the safety profile and potential sideeffects of PTH analogues administered in humans. Approach: We conducted a systematic review of multiple databases analysing papers within the last 10 years. All studies involving the use of PTH analogues in humans were included. All animal studies were excluded. Appropriate statistics regarding patient's age, gender, site of fracture, teriparatide treatment regime, clinical outcomes and imaging outcomes were extracted, analysed and summarized. Results: A total of 10 observational studies and 2 randomized controlled trials were evaluated in this study. With administration of teriparatide (PTH1-34), the mean time to 100% disappearance of fracture site pain was 3.1 months ± 0.7 months. Delayed or non-union fractures achieved bony bridging in 4.3 months. For new fractures treated non-surgically, there have been reports of shorter time to cortical bridging in the treatment group (7.4 weeks, n = 34, p = 0.006) as compared to the control group (9.1 weeks, n = 34). Lastly, a total of 8 out of 254 patients (3.1%) experienced mild side effect from teriparatide administration. Conclusion: Teriparatide shows promise to be a viable option for the treatment of fractures. Although initial studies do prove encouraging, greater evidence is needed to evaluate the optimal dosing regimen and the patient and fracture types that would achieve the best response.

Key words: Parathyroid Hormone (PTH), Magnetic Resonance Imaging (MRI), analogues administered, optimal dosing regimen, imaging outcomes, Computed Tomography (CT)

INTRODUCTION

The use of teriparatide (PTH 1-34) is approved for use in patients who are at high risk for osteoporotic fractures. Its anabolic effects, via intermittent daily administration has been shown to increase bone mass by 10-15% per year and decrease risk of vertebrae fracture by 66% in osteoporotic individuals (Etoh and Yamaguchi, 2010; Ryder *et al.*, 2010; Heaney, 2003). In addition, numerous animal studies have shown that teriparatide anabolic effects promote callus formation and bony union in various long bones (Bukata and Puzas, 2010). Its potential in augmenting fracture healing has sparked multiple off-labelled use of teriparatide in fracture healing in humans. Current literature provides anecdotal evidences that teriparatide

Corresponding Author: Wen Wei Gerard Ee, Department of Orthopaedics, Faculty of University Orthopaedics,

National University Hospital (S) Pte Ltd, Hand and Reconsstructive Microsurgery Cluster,

Lower Kent Ridge Road Singapore 119074, Singapore

shows promise as a viable pharmacological therapy in assisting with fracture healing (Whyte *et al.*, 2007; Oteo-Alvaro and Moreno, 2010; Gagnon *et al.*, 2010; Chintamaneni *et al.*, 2010; Paul *et al.*, 2010; Brunnemann *et al.*, 2010; Aspenberg *et al.*, 2010).

Teriparatide (PTH 1-34) is a synthetic polypeptide hormone manufactured via recombinant DNA technology. It contains the first 34 amino acid segment of the full length Parathyroid Hormone (PTH 1-84). The anabolic effects of teriparatide on bones are associated with enhanced trabecular connectivity, increased cortical thickness and stronger microarchitectural mechanical strength (Canalis et al., 2007; Lindsaym et al., 2007). The mechanism by which it achieves this is postulated to involve all stages of fracture healing. Nakajima et al. (2002) suggests that the increased proliferation of chondrocyte, osteoblastic cells, bone matrix protein progenitor and osteoclastogenesis explains the favourable response of teriparatide towards bone formation (Nakajima et al., 2002). Additionally, its effects are not limited by different bone surfaces with enhanced bone formation observed among endosteal, periosteal and trabecular bones (Dempster et al., 2001).

In non-osteoporotic individuals, off-label use of teriparatide encompass its use for (1) delayed or nonunion fractures that failed surgical intervention, (2) delayed or non-union fracture that failed conservative management, (3) new fractures treated with surgical intervention and (4) new fractures managed conservatively. The efficacy of teriparatide is yet to be fully studied as there is a lack of larger well designed studies to evaluate its efficacy and current literature contains papers mostly with level IV evidence.

This review paper aims to review all literature published within the last decade, where PTH analogues was used to aid new fractures or delayed or non-union fractures in humans. Also, we seek to compare the clinical efficacy of PTH analogues in particular teriparatide in contrast to conventional management for fracture healing. Lastly, we aim to evaluate the safety profile and potential side-effects of teriparatide administration in humans.

MATERIALS AND METHODS

A PubMed search was performed to identify all literature on the effect of PTH analogues on fracture healing or delayed or non-union in human subjects. The following key words were used: 'teriparatide', 'Parathyroid Hormone (PTH) analogues', 'fracture healing', 'human', 'non-union' and 'delayed union.' Detailed extraction of the data was carried out according to the search criteria. Further papers were identified through manual searches of the bibliography of the papers identified electronically. The inclusion criteria were all human studies published within the last 10 years involving only adults (age 18 and above). We analysed all clinical outcomes, clinical examination findings, radiological signs of fracture healing and functional assessment scores. All animal studies were excluded.

Appropriate statistics regarding patient's age and gender, site of fracture, dosage and length of treatment with teriparatide and clinical and imaging outcomes were extracted. To reduce bias, papers that did not include any new clinical trials but merely referenced another human trial, while focusing mainly on animal models, were not included. Of 356 papers identified initially, 12 papers met our criteria for eligibility. A total of 10 observational studies and 2 randomized controlled trials, 1 of which involving PTH (1-84) were included in this study. All data extracted from the papers were summarized into Table 1 and 2. Some data such as patients co-morbid could not be compared owing to much variation in presentation of data among the 12 journals.

RESULTS

Demographics: A total of 288 patients with 292 fractures treated were evaluated in this study (Table 1). The mean age of the patients were 62.0 years and ranged from 18-93 years. A total of 43 males (14.9%) and 245 females (85.1%) were involved. Fractures involving various anatomical sites were evaluated. Fracture sites include the sternum (1, 0.3%), ribs (3, 3%)1.0%), humerus (14, 4.8%), radius (107, 36.6%), wrist (4, 1.4%), vertebrae (54, 18.5%), pelvis (26, 8.9%), femur (40, 13.7%), tibial (15, 5.1%), foot (18, 6.2%) and ankle (4, 1.4%). 6 fracture sites were not indicated. 3 fractures (1.0%) were delayed or non-union fractures that had failed surgical intervention, 153 fractures (52.4%) were delayed or non-union fractures that had failed conservative management. 34 new fractures (11.6%) were treated primarily with surgery and 102 new fractures (34.9%) were managed conservatively.

A total of 254 out of 288 patients had daily injection of subcutaneous teriparatide. The remaining 34 patients were administered a placebo drug. Majority of the patients (218, 75.7%) were administered 20µg day⁻¹ dosing of teriparatide. 2 patients (0.7%) were administered 60 µg day⁻¹, 34 patients (11.8%) were administered 40 µg day⁻¹ and 34 patients (11.8%) were administered placebo. Of those administered teriparatide, mean dosage time was 4.4 months ±4.0 months. The minimum duration was 18 months.

Am. Med.	J.	3	(2):	220-227,	2012
----------	----	---	------	----------	------

First Author	Sample	Age of Patient	Fracture (n)	Fracture(#)	Modality to	Treatment done before
1 not rudioi	Size (n)	(Gender)	r racture (il)	Characteristic/Bone	assess fracture	initiation of PTH (1-34)
M P. Whyte	1	56y / (F)	3	Spontaneous Right 4 th Metatarsal (MT) stress # Spontaneous Left 5 th MT stress # Spontaneous Right Proximal Femur #	X-Ray	Nil
A O. Alvaro	1	32y / (M)	1	Atrophic Non-union Right diaphyseal Humerus # (sustained after trauma)	X-Ray	Intramedullary Osteosynthesis with Hackethal technique with 2 elastic nails
C. Gagnon	1	53y / (F)	2	Non-union Left Femoral # (sustained after minimal trauma) Pseudo-fracture of the Right Femur	X-Ray	Gamma Nail Surgery Nil
S. Chintamaneni	1	67y / (M)	1	Atrophic Non-union Body of Sternum # (oblique #, sustained after trauma)	CT / MRI	Nil
P T. Rubery	3	91y / (F)	3	Delayed Union type 3 Odontoid # (sustained after trauma)	СТ	Rigid Cervical Collar (8 weeks)
		84y / (F)		Delayed Union type 3 Odontoid # (sustained after trauma)	X-Ray / CT	Halo Vest (9 weeks) thereafter rigid cervical collar (5 weeks)
		82y / (F)		Delayed Union type 3 Odontoid # (sustained after trauma)	СТ	Halo Vest (13 weeks) thereafter soft cervical collar
P. Aspenberg	34 34 34	$61.4y \pm 8.6 / (F)$ (45–85y)	102	Acutely Acquired (<10 days) Unilateral Dorsally Angulated Distal Radius #	X-Ray / CT	reduction and immobilization)
S V. Bukata	143	Not stated 29 (M) 114 (F)	143	Unhealed Fracture (> 6 mth) at a wide variety of anatomical sites - Spine (48), Ribs (3), Pelvis (26), Femur (19), Tibial (11) Foot (16) Humerus (10) Wrist (4)	X-Ray / CT	Not stated
	1	58y / (M)	1	Delayed union of tibia and fibula #		Casting (4 months) thereafter partial weight bearing (2 months)
C E Brunnemann	1 1	93y / (F) 71y / (F)	1 1	Non-union of a Odontoid # Periprosthetic femoral fracture (type 3) (sustained after trauma)	X-Ray	Cervical Collar (9 months) External mono-lateral fixator applied followed with administration of PTH (1-34) 2 months later
	1	53y / (F)	1	Periprosthetic Left distal femoral # (sustained after trauma)		Reduction of # with fixed angle distal condylar buttress plate and autologous cancellous bone together with PTH (1-34)
	1	18y / (M)	1	Left Radial Shaft # (sustained after trauma)		Osteosynthesis with bone grafting (failed) followed with autologous tri-cortical iliac crest bone graft with PTH (1-34)
G. Resmini	1	79y / (F)	1	Acutely Acquired Left Proximal Humerus # (sustained after trauma)	X-Ray	Conservative Treatment with soft bandage as patient is already on PTH (1-34) for past 10 months owing to spontaneous vertebral compression # at T8 and T11
T P. Knecht	1	47y / (M)	1	Acutely Acquired Right Tibial and Fibula # (sustained after trauma)	X-Ray	Intramedullary Rod in Right Tibial followed with administration of PTH (1-34) starting 7 weeks later
U. Tarantino	29 ^a	$\begin{array}{l} 65.2y\pm 18.4 \\ (9M 20F) \\ (25-93y) \end{array}$	30	Fracture at a wide variety of anatomical sites – Femur (16), Vertebrae (2), Tibial (2), Ankle (4), Humerus (2), Radius (4)	X-Ray	Surgical Intervention followed with administration of PTH (1-34)
Total	288	62.0y / (43M 245F)	292	Sternum (1), Ribs (3), Humerus (14), Radius (107), Wrist (4), Vertebrae (54), Hip (26), Femur (40), Tibial (15), Foot (18), Ankle (4), unknown (6)		Delayed/non-union fractures that had failed surgical intervention (3), delayed/non-union fractures that had failed conservative management (153), acutely acquired fractures treated surgically (34) and acutely acquired fractures managed conservatively (102)

Table 1: Summary of Studies of Teriparatide on Fracture Healing (Patient and Feature Characteristics)

a: Tarantino *et al.* (2007) presented on 34 surgical patients who received teriparatide, however, only 29 out of the 34 patients were diagnosed and treated for fractures.

Major results: Majority of the studies analysed the efficacy of teriparatide via clinical and radiological outcomes. Clinical outcomes measured mostly involved pain scores with some journals measuring ability to mobilise, range of motion and function. Radiological findings involved the use of X-Rays, Computed

Tomography (CT) scans or Magnetic Resonance Imaging (MRI) to assess for callus formation, bony bridging, reduction of fracture line and complete bony union. As not all studies were written with similar outcome measures, the following results were taken from a distinct subset of the 12 journals involved.

Am. Med. J. 3 (2): 220-227, 2012

First Adder User 133/300 semigration (13.9) Clinical Outcome League (2) M P. Whye Messaread Quog 4 anomb. 6 sewales 00: rother (10.9) Clinical Outcome Cannual house (2) Cann			Dose of	Time to bony	Duration of				
M.P. Wayse Metauraal 30g 4 months (5 weeks) 9000 reduction in ford in pain (2 months) in addition (not in pain the pain (2 months) in addition (not in pain the pain (2 months) in addition (not in pain the pain (2 months) in addition (not in pain the pain A O. Alvaro Haments 20g 3 months 5 months (3 months) in addition (not in pain the pain (2 months) - addition with callum. (1 months) - addition (1 more match pain the pain the pain the pain the pain the pain A O. Alvaro Haments 20g 3 months 5 months (3 months) - forder (not in pain the pain	First Author	Bone	PTH (1-34)/day	starting PTH (1-34)	PTH (1-34)	Clinical Outcome		Imaging Outcomes	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	M P. Whyte	Metatarsal	20ug	4 months	16 months	(6 weeks) -90% reduction	in foot	(2months) – bony bridging and	
Kalanzani Hatamisa (4 anomb) (4 ano	with whyte wietataisai		2046	4 months	To monuis	pain and 50% reduction in right thigh pain		reduction of fracture line	
A. D. Abura Famir 4 aouths Souths off (PTH (1-34) putient remain pain field of affaiture size pain space of the space of the			Metatarsal		10 months	(4 months)-disappearance	of all # pain	(2months) – calcification with	
Ferrar Ferrar Ronaths Smonths Smonths Smonths Smonths Gametal Gametal <thgametal< th=""> <thgametal< th=""> <thgam< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>callus, (10months) – 50% further of</td></thgam<></thgametal<></thgametal<>								callus, (10months) – 50% further of	
A O. Alvico Humens 20kg 3 months 5 months C for control or light free of all fractures size pain (4) fractures is and pain A O. Alvico Humens 20kg 3 months 5 months C for control or light free of all fractures size pain (3) months			Femur		4 months	8 months off PTH (1-34)	natient	fracture line gone with bony bridging	
A O. Alvaro Panera 20g 3 months 5 months 6 months 100% reduction in a pain with complex leading (6 months) - 100% reduction in a pain with complex leading (6 months) - 100% reduction in a pain with 1 months 1111 (1-3), painera 1 months 1111 (1-3), painera 2 months of TTH (1-3),			I ciliui		4 monuis	remains pain free of all fra	acture site pain	(4 months) - significant improvement	
A O, Alvoor Humens 20ge a months 5 months 7 months						1	1	with reduction of fracture line and	
A. O. Alvaro Humera 20/g 3 months 5 months (5 months) - 100% exclusion in of pain with complex (K10) with (1, 2) partial 6 months - boxy bridging with complex (K10) with (1, 2) partial 6 months - boxy bridging with complex (K10) with (1, 2) partial 6 months - boxy bridging with complex (K10) with (1, 2) partial 6 months - boxy bridging with complex (K10) with (1, 2) partial C. Gagoon Penar 20/g N/A 13 months 7 months - 100% reduction in pain with increased mobility 2 months of PTH (1, 3), partial with increased mobility 2 months of PTH (1, 3), partial partial (6 months) - complex hashing with increased mobility 2 months of PTH (1, 3), partial partial (7 months) - 100% reduction in match pain able to return to exercise regime of mothes (1, 2) months - boxy bridging with complex (K10) weeks) - 100% reduction in moth - boxy with returned to exercise regime of mothes (1, 2) weeks - 100% reduction in moth - boxy with returned to exercise regime of mothes - boxy with reture mothes - b								bony union	
$ \begin{array}{c c c c c c } \ & \ & \ & \ & \ & \ & \ & \ & \ & \ $	A O. Alvaro	Humerus	20µg	3 months	5 months	(5 months) – 100% reduction in # pain with		(3 months) – bony bridging with	
C. Gagnon Ferrur 20µg NA 13 months 17 months - 100% reduction is # piat. 6 months) - complete healing						1 month off PTH (1-34)	patient	-complete healing (6 month)	
C. Gagoon Ferrur 20g N/A 13 monthy [7 monthy - 100% reduction: in # pine) with increased mobility pare in right in set of monthy and in reduction in # pine). (8 monthy - complete healing of right regulation and permanes of boxy pare in right in right regulation and permanes of boxy pare in result regulation in # pine). (8 monthy - complete regulation in the pine). (8 monthy - complete regulation in result regulation). S. Chintamaneni Stemum 20g 2 monthy - 200% regulation in the pine. (7 monthy - 100% reduction in # pine). (7 monthy - 100% reduction in # pine). P T. Rubery C2 Vertebra 20g 2 monthy - 3 monthy - 3 monthy 1 monthy - 100% reduction in the pine. (7 monthy - 100% reduction in the pine). (7 monthy - 100% reduction in the pine). P Appenderg 4 monthy 1 monthy - 100% reduction in the pine. (7 monthy - 100% reduction). (7 monthy - 100% reduction). (7 monthy - 100% reduction). P. Appenderg 4 monthy 1.8 monthy 4 monthy 4 monthy 4 monthy 1.8 monthy (7 monthy - 100% reduction). (7 monthy - 100% reduction). P. Appenderg 4 monthy 4 monthy 4 monthy 4 monthy 4 monthy 1.8 monthy (7 monthy - 100% reduction). (7 monthy - 100% reduction). P. Appenderg 20g 7 monthy - 100% reduction. (7 monthy - 100% reduction). (7 monthy - 100% reduction). <td></td> <td></td> <td></td> <td></td> <td></td> <td>returned to work</td> <td>F</td> <td>– complete healing</td>						returned to work	F	– complete healing	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	C. Gagnon	Femur	20µg N/A		13 months	(7 months) - 100% reduction in # pain		(8 months) - complete healing of	
S. Chintamaneni Stemum 20µg 3 months > 9mth $Pipting Pipting Piptin$						with increased mobility		right pseudo# and appearance of bony	
S. C. Dintamanen S. Dintamanen S. C. Dintamanen S. Dintama						2 monus on PTH (1-54), pain in right thigh	patient reported	2 months off PTH (1-34) pseudo# of	
S. Chintananeni Stemu 20µg 3 months > 9mh 9 months) - 100% reduction in a pain, in a pain, and callus frameworks - complete frameworks - compl						puin in right ungi		right femur re-appeared	
P T. Rubery C 2 Vertebra 2 0 ge 2 months $> 2 months > 2 months > 2 month > 3 month > 10 weeks > 100% reduction in neck pain (2 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) month) matter cancellous bone formation (3 - 0 month - 0 month) month) matter cancellous bone formation (3 - 0 month - 0 month) matter cancellous bone formation (3 - 0 month - 0 month) month) matter cancellous bone formation (3 - 0 month - 0 month) month) month and formation (3 - 0 month - 0 month) month) month) month and formation (3 - 0 month - 0 month) m$	S. Chintamaneni	Sternum	20µg	3 months	>9mth	(9 months) - 100% reduct	tion in # pain,	(3 months) – bony bridging with	
P T. Rubery P T						able to return to exercise	regime of	decreased fracture gap and callus	
P. T. Rubery C2 Vertebra 2000 2 months > 2 month C2 months / 100% reduction in neck pain C2 months / 100% reduction C2 months / 100% reduction C2 months / 100% reduction C3 months / 100% reduction C4 months / 100% reduction <td></td> <td></td> <td></td> <td></td> <td></td> <td>weight lifting</td> <td></td> <td>formation (9 months) – complete</td>						weight lifting		formation (9 months) – complete	
1 1 <td>P T. Ruberv</td> <td>C2 Vertebrae</td> <td>20ug</td> <td>2 months</td> <td>> 2 mth</td> <td>(2 months) - 100% reduc</td> <td>tion in neck pain</td> <td>(2 months) – bony bridging with</td>	P T. Ruberv	C2 Vertebrae	20ug	2 months	> 2 mth	(2 months) - 100% reduc	tion in neck pain	(2 months) – bony bridging with	
3 months >3 months >3 months >3 months > 23 months 10 weeks) - 100% reduction (4 months) - bony unior P. Aspenherg Radius Placebo 9.1 weeks 1.8 months 9.4 months (4 months) - 100% reduction (3 forms) - bony bridging in at least questionmair (assess pain and functional dight) (7.4 weeks) - 4 our of 4 cortical bridging (7.4 weeks) - 4 our of 4 cortical bridging in at least questionmair (assess pain and functionace between) 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our of 4 cortical bridging in at least 3 of four cortices (11.9 weeks) - 4 our			10			. ,	1	mature cancellous bone formation	
n neck pain neck pain				3 months	> 3mth	(2.3 months / 10 weeks) -	- 100% reduction	(3 months) – bony union	
 P. Aspenberg Radius Placebo 9.1 weeks 1.8 months Planet Acted Wine Caputation (PRWE) (9.1 weeks) lowy bridging in at least or function set of a contral bridging control bridging in at least of function (PRWE) low bridging in the least of function (PRWE) low bridging in the least or low bridgin (PRWE) low bridging in the least or low bridging in the				1 months	Amth	in neck pain (4 months) 100% reduct	tion in pack pain	(4 months) hony union	
2 Production 3 of four cortics (11 3 weeks) – 4 out of 4 ortical bridging improvement compared to baseline. Nat statistically significance between placebo and PTH (1-34) treatment groups. 3 of four cortics (11 3 weeks) – 4 out of 4 ortical bridging of 4 ortical bridgin	P. Aspenberg	P Aspenberg Radius		Placebo 9.1 weeks		Patient-Rated Wrist Evaluation (PRWE)		(4 months) – bony union (9.1 weeks) – bony bridging in at least	
SV. Bukata Range of # 20µg 7.4 vecks 14 vecks) - 100 + 100	1 8					questionnaire (assess pain	and function	3 of four cortices (11.3 weeks) – 4 out	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						scores) and grip strength s	showed significant	of 4 cortical bridging	
S V, Bukata Range of # 20µg 7.4 weeks 3.8 weeks 4.8 weeks						improvement compared to	o baseline.	(7.4 weeks) - bony bridging in at least	
20µg 7.4 weeks (8.8 weeks) - bony bridging in at least 3 of four cortices (11.0 weeks) - 4 out of 4 cortical highing S V. Bukata Range of # 20µg Varied, average not stated Unit intropactic (10 weeks) - 100% pain reduction at fracture site to be healed (12 weeks) - 97.0% had radiological and clinical unit of fractures. 4% (6/145) demonstrated partial reduction at fracture site or fracture site (14/145) of patients (14/145) of patients (14/145) failed to observe radiographic nor of fracture but clinically functioned as a healed fracture. 3% (14/145) failed to observe radiographic nor of fracture but (10 months) - No to the H7 FH intervention (see Table 1) C E Brunnemann Femur 60µg Not stated 1.4 months (2 months) - patient able to mobilize (10 weeks) - motion of fracture but clinically functioned as a healed fracture. 3% (14/145) failed to observe radiographic nor clinical improvements with other intervention (see Table 1) G. Resmini Radius 60µg 1.4 months Not stated (10 weeks) - motion of shoulder fracture healing (6 months) - pseducarthrosis fully stable consolidation (see Table 1) G. Resmini Humerus 20µg 25 days (on PTH prior to #) Not stated (10 weeks) - motion of shoulder fracture healing (2 days) after # - motion of shoulder fracture healing (2 days) after # - motion of shoulder fracture healing 20µg T P. Knecht Tibia Fibula 20µg not stated 6 months (1 A months) after # - motion of shoulder fresumed running Patients =						placebo and PTH (1-34) t	reatment groups.	of 4 cortical bridging	
SV. Bukatan Range of # Tibia & Fibula 20µg Varied, average not stated (140) or full orthopadie to be healed (7 weeks) - 100% pin to de verial articuter site to be healed (7 weeks) - 100% pin to de verial articuter site to be healed (141) (145) of patients had 100% reduction (141) (40) construct union of Tactures 4W (141/45) of patients had 100% reduction (141/45) of patients had 100% reduction had 100 % had had 100 % h				20µg	7.4 weeks	F	5F	(8.8 weeks) – bony bridging in at least	
S V. Bukata S V. Bukat				40µg	8.8 weeks			3 of four cortices (11.0 weeks) - 4 out	
S. V. Bukala Radige of # 20µg Varted, average Onlin orthopaceue (7 Weeks) - 10% pain (12 Weeks) - 9/2.% 12 Weeks) - 10% for the 10 We		D 6#	20	X7 · 1	TT (1 (1))	(7 1) 1000/	(12 1) 07 20(of 4 cortical bridging	
C 2 Verebrae C	S V. Bukata	Tibia & Fibul	20µg	varied, average	until ortnopaedic provider deems #	(/ weeks) – 100% pain reduction at fracture site	(12 weeks) = 97.2% (141/145) of patients	12 weeks) – 93.0% had radiological (and clinical union of fractures 4%)	
C E Brunnemann Femur 60µg Not stated 1.4 months 2 (2 months) – patient of pain at the fusion or fracture site of pain at the fusion or fracture site 0 months) – stated Not observe radiographic or Cirical Proprovements C E Brunnemann Femur 60µg Not stated 1.4 months 2 (2 months) – patient (10 weeks) – stable consolidation of fracture Not ethat PTH stable consolidation (see Table 1) Femur 20µg 2.3 months Not stated (10 weeks) – (1.34) for 10 mh prior to #) (14 months) Not stated (25 days) at et motion of shoulder T P. Knecht Tibial Fibula 20µg 25 days (on PTH prior to #) 18 months (4 weeks) after # – motion of shoulder reduction of fracture with prior to #) reduction of fracture weet fracture with prior to #) T P. Knecht Tibial Fibula 20µg not stated 6 months 6 months 6 months e months reduction of shoulder T r. Knecht Tibial Fibula 20µg not stated 6 months 6 months 6 months e clinical and radiological improvements starbuted to treat- resumed running T P. Knecht Tibial Fibula 20µg Not stated 6 months 6 months		C2 Vertebrae	a	not stated	to be healed	(6 weeks) – 100% pain	had 100% reduction	(6/145) demonstrated partial	
C E Brunnemann Femur 60µg Not stated 1.4 months (2 months) – patient able to mobilize (10months) – mobilize Not stated in of fracture Not stated in of fracture C E Brunnemann Femur 20µg 2.3 months Not stated (10months) – mobilize Not stated in of fracture Not stated in of fracture 1-34 used in of fracture Not stated in of fracture Not state (10 weeks) – mobilize (6 months) – pedient intervention is stabilized G. Resmini Radius 60µg 25 days (on PTH (1-34) Not state Not state (25 days) after # - bry bridging and indio logical improvements attributed to treatment intervention is resumed running running runned (N3 shorted) Not stated 9.7mth ± 7.77 26/29 (89.6%) showed interventer is tributed to resume running ru						reduction at fracture site	of pain at the fusion	radiographic union of fracture but	
C E Brunnemann Femur 60µg Not stated 1.4 months (2 months) – patient able to mobilize (10months) – Note that PTH able to mobilize Stable consolidation is 1-34 used in intervention (see Table 1) C E Brunnemann Femur 20µg 2.3 months Not stated (10 weeks) – (for months) – pseumentrosis fully stabilized intervention (see Table 1) G. Resmini Humerus 20µg 25 days (on PTH (1-34)) 1.4 months Not stated (25 days) after # – bony bridging and (1-34) for 10 mth prior to #) T P. Knecht Tibial Fibula 20µg 25 days (on PTH (1-34)) 18 months (4 weeks) after # – concyber range of motion of shoulder prior to #) resumed running The speed of clinical and radiological improvements attributed to treatment with PTH (1-34) T P. Knecht Tibial Fibula 20µg Not stated 6 months (1.4 months) after PTH uning The speed of clinical and radiological improvements attributed to treatment with PTH (1-34) U. Tarantino Range of # 20µg Not stated 9.7mth ± 7.57 26/29 (8/6) showed 24/29 patients (82.7%) achieved cornel treatment 10.5 mths ± 7.3 mths), scale (VAS) before and scale on visual analogue scale (VAS) before and scale (VAS) befo							or fracture site	clinically functioned as a healed	
C E Brunemann Femur 60μg Not stated 1.4 months (2 months) – patient able to mobilize (100mths) – (Note that PTH intervention (25 days) after # -bory bridging and (26 days) after # -bory bridging and (27 days) after # -bory bridging and (26 days) af								tracture. 3% (4/145) failed to observe	
 able to mobilize be to mobilize complete many complete	C E Brunnemann	Femur	60µg	Not stated	1.4 months	(2 months) - patient		(10months) – Note that PTH	
k Femur 20µg 2.3 months Not stated (10 weeks) - (10						able to mobilize		stable consolidation 1-34 used in	
Femur 20μg 2.3 months Not stated (10 weeks) - (6 months) - pseduoarthrosis fully fracture healing statilized Radius 60μg 1.4 months Not stated (10 weeks) - (25 days) dfet # - bony bridging and (25 days) dfet # - bony bridging and (1-34) for 10 mth (1-34) for 10 mth (1-34) for 10 mth prior to #) 18 months (4 weeks) after # - reduction of fracture line T P. Knecht Tibial Fibula 20μg not stated 6 months (1.4 months) for PTH (1-34) Radiological improvements attributed to treatment with PTH (1-34) T P. Knecht Tibial Fibula 20μg not stated 6 months (1.4 months) after PTH (1-34) Radiological indings showed fracture (1-34) introduced - patient resumed running Radiological indings showed fracture (1-34) introduced - patient (1-34) Radiological improvements attributed to treatment with PTH (1-34) U. Tarantino Range of # 20μg Not stated 9.7mth ± 7.57/ (26/29 (89.6%) showed 24/29 patients (82.7%) achieved (1mth to 18 mth) 24/29 patients (82.7%) achieved (1mth to 18 mth) 24/29 patients (82.7%) achieved (1mth to 18 mths) 5/29 patients (17.3%) fracture healing after treatment 5/29 patients (17.3%) fracture healing after treatment 5/29 patients (17.3%) fracture healing after treatment 5/29 patients (17.3%) fracture healing after treatment 2.2 mt								of fracture conjunction	
Femur 20μg 2.3 months Not stated (10 weeks) - (6 months) - pseduoarthrosis fully fracture healing (10 weeks) - (6 months) - pseduoarthrosis fully stabilized Radius 60μg 1.4 months Not stated (10 weeks) - (25 days) after # - bony bridging and G. Resmini Humerus 20μg 25 days (on PTH (1-34) for 10 mth prior to #) 18 months (4 weeks) after # - reduction of fracture line T P. Knecht Tibial Fibula 20μg not stated 6 months (1.4 months) after PTH (1-34) Radiological inprovements attributed to treatment with PTH (1-34) introduced - patient U. Tarantino Range of # 20μg Not stated 9.7mth ± 7.57 / 26/29 (89.6%) showed 24/29 patients (82.7%) achieved (1mth to 18mth) scale (VAS) before and after treatment 24/29 patients (82.7%) achieved decrease in pain perception complete fracture healing (duration of based on visual analogue treatment 2.2 mths ± 0.8 mths) Total 34 patients = placebo 4.4mths ± 4.0 218 patients = 20µg/day (1mth to 18 mths) scale VI = 0.8 mths)								with other	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								(see Table 1)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Femur	20µg		2.3 months	Not stated	(10 weeks) -	(6 months) - pseduoarthrosis fully	
Radius60µg1.4 monthsNot state(25 days) after # - bony bridging andG. ResminiHumerus20µg25 days (on PTH (1-34) for 10 mth prior to #)18 months(4 weeks) after # - complete range of motion of shoulder The speed of clinical and radiological improvements attributed to treatment with PTH (1-34)T P. KnechtTibial Fibula20µgnot stated6 months(1.4 months) after PTH (1-34) introduced - patient prior to #)Radiological findings showed fracture union resumed running The speed of clinical and radiological improvements attributed to treatment with PTH (1-34)U. TarantinoRange of #20µgNot stated9.7mth \pm 7.57/ (26/29 (88.6%) showed24/29 patients (82.7%) achieved (1mth to 18mth) decrease in pain perception scale (VAS) before and after treatment24/29 patients (82.7%) achieved treatment 10.5 mths \pm 7.7 mths), scale (VAS) before and after treatmentTotal34 patients = placebo 218 patients = 20µg/day 2 patients = 60µg/day4.4mths \pm 4.0 218 patients = 40µg/day 2 patients = 60µg/day4.4mths \pm 4.0							fracture healing	stabilized	
 C. Reshinin Futureus 20μg 2.5 days (of PTH 18 months (4 weeks) after #- reduction of fracture line (1-34) for 10 mth prior to #) T. P. Knecht Tibial Fibula 20μg not stated 6 months (1.4 months) after PTH (1-34) U. Tarantino Range of # 20μg Not stated 9.7mt ± 7.57 / 26/29 (89.6%) showed 24/29 patients (82.7%) achieved (1mth to 18mth) decrease in pain perception complete fracture healing (duration of based on visual analogue treatment 0.5 mth ± 7.7 mths), scale (VAS) before and 5/29 patients (17.3%) fracture healing after treatment Total 34 patients = placebo 218 patients = 20µg/day (1mth to 18 mths) 34 patients = 40µg/day 2 patients = 60µg/day 	C Deservisi	Radius	60μg 20	25 January (and DTELL	1.4 months	Not state		(25 days) after # – bony bridging and	
result of should r motion of shoulder prior to #) motion of shoulder T P. Knecht Tibial Fibula 20µg not stated 6 months (1.4 months) after PTH Radiological findings showed fracture U. Tarantino Range of # 20µg Not stated 9.7mth ± 7.57 / 26/29 (88.6%) showed 24/29 patients (82.7%) achieved U. Tarantino Range of # 20µg Not stated 9.7mth ± 7.57 / 26/29 (88.6%) showed 24/29 patients (82.7%) achieved Total 34 patients = placebo 4.4mths ± 4.0 still on-going (current duration of treatment 2.2 mths ± 0.8 mths) Total 34 patients = 20µg/day 20µg/day 218 patients = 60µg/day 20µg/day	G. Resmini	Humerus	20µg	(1-34) for 10 mth	18 months	(4 weeks) after # –		reduction of fracture line	
T P. Knecht Tibial Fibula 20μg not stated 6 months (1.4 months) after PTH (1-34) Radiological findings showed fracture (1-34) introduced – patient U. Tarantino Range of # 20μg Not stated 9.7mth ± 7.57 / 26/29 (88.6%) showed 24/29 patients (82.7%) achieved (1mth to 18 mth) U. Tarantino Range of # 20μg Not stated 9.7mth ± 7.57 / 26/29 (88.6%) showed 24/29 patients (82.7%) achieved (1mth to 18 mth) Total 34 patients = placebo 4.4mths ± 4.0 still on-going (current duration of 218 patients = 20µg/day 4.4mths ± 4.0				prior to #)		motion of shoulder			
PTH (1-34)PTH (1-34)T P. KnechtTibial Fibula 20μ gnot stated6 months (1.4 months) after PTHRadiological findings showed fracture(1-34)(1-34) introduced – patientunionW. TarantinoRange of # 20μ gNot stated $9.7\text{mth} \pm 7.57 / 26/29$ (88.6%) showed $24/29$ patients (82.7%) achievedU. TarantinoRange of # 20μ gNot stated $9.7\text{mth} \pm 7.57 / 26/29$ (88.6%) showed $24/29$ patients (82.7%) achievedU. TarantinoRange of # 20μ gNot stated $9.7\text{mth} \pm 7.57 / 26/29$ (88.6%) showed $24/29$ patients (82.7%) achieved(Imuth to 18 mth)decrease in pain perceptioncomplete fracture healing (duration of based on visual analoguetreatment 10.5 mth ± 7.7 mths), scale (VAS) before and after treatment $5/29$ patients (17.3%) fracture healing after treatmentTotal 34 patients = placebo $4.4\text{mths} \pm 4.0$ 218 patients = 20μ g/day $4.4\text{mths} \pm 4.0$ 218 patients = 40μ g/day 2μ g/day 2μ g/day 2μ g/day						The speed of clinical and	radiological improveme	ents attributed to treatment with	
IP. KnechtHbial FibulaZoughot stated6 months (1.4 months) after PTHRadiological induings showed fracture (1-34) introduced – patientU. TarantinoRange of #20µgNot stated9.7mth \pm 7.57 /26/29 (88.6%) showed24/29 patients (82.7%) achieved (1mth to 18mth)U. TarantinoRange of #20µgNot stated9.7mth \pm 7.57 /26/29 (88.6%) showed24/29 patients (82.7%) achieved (1mth to 18mth)U. TarantinoRange of #20µgNot stated9.7mth \pm 7.57 /26/29 (88.6%) showed24/29 patients (82.7%) achieved (1mth to 18mth)Total34 patients = placebo 218 patients = 20µg/day 2 patients = 40µg/day 2 patients = 60µg/day4.4mths \pm 4.0	TD K 1	ar:1 : 1 r:1 1	20	1	C 4	PTH (1-34)			
U. Tarantino Range of # 20μ g Not stated 9.7mth \pm 7.57 / $26/29$ (88.6%) showed 24/29 patients (82.7%) achieved (1mth to 18mth) decrease in pain perception complete fracture healing (duration of based on visual analogue treatment 10.5 mths \pm 7.7 mths), scale (VAS) before and 5/29 patients (17.3%) fracture healing after treatment still on-going (current duration of treatment 2.2 mths \pm 0.8 mths) Total 34 patients = placebo 4.4mths \pm 4.0 218 patients = 20µg/day 2 patients = 60µg/day 2 patients = 60µg/day	I P. Knecht	Tibial Fibula	20µg	not stated	6 months	(1.4 months) after PTH (1-34) introduced – patier	at .	Radiological findings showed fracture	
U. Tarantino Range of # 20μg Not stated 9.7mth ± 7.57 / 26/9 (88.6%) showed 24/29 patients (82.7%) achieved (1mth to 18mth) 46crease in pain perception complete fracture healing (duration of based on visual analogue treatment 10.5 mths ± 7.7 mths), scale (VAS) before and 34 patients = placebo 218 patients = 20µg/day 218 patients = 20µg/day 2 patients = 60µg/day 2 patients = 60µg/day						resumed running			
U. Tarantino Range of # 20μ g Not stated $9.7mt \pm 7.57 / 26/29$ (88.6%) showed $24/29$ patients (82.7%) achieved (1mth to 18mth) decrease in pain perception complete fracture healing (duration of based on visual analogue scale (VAS) before and after treatment $5/29$ patients (17.3%) fracture healing after treatment 2.2 mths ± 0.8 mths) Total 34 patients = placebo 218 patients = 20µg/day $4.4mths \pm 4.0$ 218 patients = $20µg/day$ 2 patients = $40µg/day$ 2 patients = $60µg/day$						The speed of clinical and	radiological improveme	ents attributed to treatment with	
U. Tarantino Range of # 20µg Not stated 9.7mt ±7.577 26/29 (89.6%) showed 24/29 patients (82.7%) achieved (1mth to 18mth) decrease in pain perception complete fracture healing (duration of based on visual analogue scale (VAS) before and after treatment still on-going (current duration of treatment 2.2 mths ± 0.8 mths) Total 34 patients = placebo 4.4mths ± 4.0 (1mth to 18 mths) 34 patients = 20µg/day 2 patients = 60µg/day 2 patients = 60µg/day			•			PTH (1-34)			
Total 34 patients = placebo 4.4mths ± 4.0 5/29 patients (17.3%) fracture healing after treatment State of visual and spue treatment 10.5 mths, scale (VAS) before and after treatment still on-going (current duration of treatment 2.2 mths ± 0.8 mths) Total 34 patients = 20µg/day (1mth to 18 mths) 34 patients = 40µg/day 2 patients = 60µg/day	U. Tarantino	Kange of #	20µg	not stated	9. /mth \pm 7.57 /	20/29 (89.6%) showed decrease in pain perceptic	m	24/29 patients (82.7%) achieved	
scale (VAS) before and after treatment 5/29 patients (17.3%) fracture healing still on-going (current duration of treatment 2.2 mths ± 0.8 mths) Total 34 patients = placebo 4.4mths ± 4.0 218 patients = 20µg/day (1mth to 18 mths) 34 patients = 40µg/day 2 patients = 60µg/day					(Tinui to Toinui)	based on visual analogue		treatment 10.5 mths \pm 7.7 mths),	
after treatment still on-going (current duration of treatment 2.2 mths ± 0.8 mths) Total 34 patients = placebo 4.4mths ± 4.0 218 patients = 20µg/day (1mth to 18 mths) 34 patients = 40µg/day 2 patients = 60µg/day						scale (VAS) before and		5/29 patients (17.3%) fracture healing	
Total 34 patients = placebo 4.4mths \pm 4.0 218 patients = 20µg/day (1mth to 18 mths) 34 patients = 40µg/day 2 patients = 60µg/day						after treatment		still on-going (current duration of	
218 patients = 20µg/day 4 patients = 40µg/day 2 patients = 60µg/day	Total		34 patients -	- nlacebo	4.4 mths + 4.0			treatment 2.2 mths \pm 0.8 mths)	
34 patients = 40µg/day 2 patients = 60µg/day	1 Otal		218 patients	= 20μg/dav	(1 mth to 18 mths)				
$2 \text{ patients} = 60 \mu \text{g/day}$			34 patients =	= 40µg/day					
			2 patients =	60μg/day					

Table 2: Summary of Studies of Teriparatide on Fracture Healing (Clinical and Radiological Outcomes

As a whole, all 12 studies have shown radiological evidence of fracture union following PTH analogue administration. This has been associated with marked improvements in clinical parameters and functional outcomes in patients treated. The mean time to 100% disappearance of fracture site pain after starting teriparatide (PTH1-34) was 3.1 months \pm 0.7 months. This was evaluated from 151 fracture sites. For the remaining fracture sites, majority of the authors documented a decrease in pain perception.

The mean time to bony bridging after starting PTH (1-34) varied widely across different fracture sites. For delayed or non-union fractures that failed conservative treatment, administration of teriparatide was associated with a mean time to bony bridging of 4.3 months. Bukata *et al.* (2009) who presented an observational cohort of 145 patients with delayed fracture healing (> 6 months) noted that 135 patients (93%) achieved radiological union of fracture with teriparatide administration within 2.8 months (Bukata *et al.*, 2009).

For new fractures that were treated conservatively, administration of teriparatide was associated with decreased time for bony bridging. This was demonstrated in a study by Aspenberg *et al.* (2010) who showed that osteoporotic distal radius fractures that were treated with teriparatide 20 μ g day⁻¹ resulted in cortical bridging within 7.4 weeks as compared to a placebo group which took 9.1 weeks (p = 0.006) (Aspenberg *et al.*, 2010). Similarly an isolated case report of a proximal humeral fracture achieved bony bridging within 3.6 weeks with teriparatide (Resmini and Iolascon, 2007).

A total of 8 patients out of 254 patients (3.1%) experienced mild side effect from teriparatide administration. 2 patients (Tarantino *et al.*, 2007) complained of dizziness and rash while 6 patients¹¹ reported mild side effects such as nausea, vomiting and headache. These 6 patients were being administered teriparatide at a dosage of 40 μ g day⁻¹. No other side effects were noted from the studies involving teriparatide administration.

DISCUSSION

Teriparatide has been shown to be beneficial in promoting fracture healing. Studies on the use of teriparatide in primary union, delayed and non-union have resulted in improvement in the time to clinical and radiological union. Chintamaneni *et al.* (2010) noted that the dramatic radiographic healing of a non-union sternal fracture was achieved only after intervention with teriparatide (Chintamaneni *et al.*, 2010). Also Rubery and Bukata (2010) attributed the rapid pain relief and bony bringing experienced by 3 patients with delayed type 3 odontoid fractures solely to the initiation of teriparatide (Paul *et al.*, 2010). Similar results have been illustrated in patients with varying ages, gender and fracture sites.

The best evidence to date involves a prospective randomized controlled study. The study analysed the effects of PTH (1-84) on fracture healing in 65 postmenopausal women with osteoporosis who had sustained a pelvic fracture. Although the PTH compound used was different (PTH 1-84 vs. PTH 1-34), the additional fifty amino acids in PTH 1-84 are inactive and the resulting bio-efficacy of the two compounds remain the same. Both are known to have similar anabolic effects although there is currently a paucity of comparative studies between the two (Verhaar and Lems, 2009). Peichl et al. (2011) found that administration of PTH 1-84 (100 μ g day⁻¹) resulted in a shorter fracture union time in primary union compared to a control group (Peichl et al., 2011). Pubic bone fracture treated with PTH 1-84 achieved fracture union in 7.8 weeks compared to 12.6 weeks a control group (p<.001). By eight weeks all fractures in the treatment group (n = 21) had healed in contrast to 4 fractures in the control group (n = 44). (Healing rate, 100% [95% CI, 86.7-100.0%] compared with 9.1% [95% CI, 2.5-21.7%]). The treatment group also had statistically significant improved clinical and functional outcomes (p<0.001) as compared to the control group (assessed with both visual analogue scale for pain and a timed up and go test).

In another prospective randomized double-blind clinical study by Aspenberg et al. (2010) the use of teriparatide (PTH 1-34) resulted in shorten time to fracture healing in conservatively treated distal radial fractures (Aspenberg et al., 2010). Time to healing was significantly shorter in the treatment group (n = 34) that received teriparatide 20 μ g day⁻¹ (7.4 weeks, p = 0.006) as compared to the control group (9.1 weeks, n = 34). Surprisingly, the study acknowledges a lack of doseresponse relationship with intermittent administration of PTH 1-34. The treatment group (n = 34) that received teriparatide 40 μ g day⁻¹ showed shorter healing time compared to the control group. This however was not statistically significant (8.8 weeks, p =0.523). Clinical outcomes measuring pain and functional results (assessed using the Patient-Rated Wrist Evaluation questionnaire and grip strength via a Jamar dynamometer) also failed to achieve statistically significant differences between the treatment groups and the control group.

For the management of delayed or non-union fractures, we evaluated the efficacy of teriparatide

against bone grafting. Treatment with bone grafting is widely accepted as the gold standard in the management of delayed or non-union fractures. We analysed two studies where patients had similar fracture sites with the main difference being the administration of teriparatide. Brunnemann et al. (2010) presented a case of a 53 year old female who sustained a left distal femoral fracture who was treated with a buttress plate and autologous cancellous bone graft together with administration of PTH (1-34) (Brunnemann et al., 2010). Fracture union was achieved in 10 weeks. In comparison, a prospective study by Gardner et al. (2008) where 31 patients with a distal femoral fracture were treated similarly but without administration of teriparatide, achieved fracture healing with a mean of 16.1 weeks (range 10-32 weeks). Another study by Brunnemann et al. (2010) showed that bone grafting together with administration of teriparatide in a nonunion radial shaft fracture (initially failed primary treatment with bone grafting) achieved union after 6 months (Brunnemann et al., 2010).

Teriparatide has also been shown to be effective as an isolated form of treatment in the management of fractures. Resmini and Iolascon (2007) presented a case of a 79 year old osteoporotic female who benefited from conservative management and intermittent teriparatide therapy following a displaced 2 part proximal humerus fracture (Resmini and Iolascon, 2007). Radiographic evidence showed bony union after 3.6 weeks while clinically, full range of motion was achieved in 7.6 weeks. In contrast, a recent study by Gupta et al. (2012) showed that displaced 2 part proximal humeral fracture treated with external fixation achieved fracture union in 6.5 weeks (range 6-8 week) (Gupta et al., 2012). Also, full range of motion was achieved in a mean duration of 16.5 weeks (range 8-32 weeks) (Gupta et al., 2012). It appears that the use of teriparatide may be a reasonable alternative with improved radiological and clinical benefits without the associated risks from external fixation such as wire and pin tract infections or loosening. Furthermore, in severely osteoporotic individuals where achieving rigid fixation in osteoporotic cancellous bone can be challenging, teriparatide would be a more viable option as compared to operative intervention.

Teriparatide can also be used as an adjunct to operative treatments. Operative management unlike isolated teriparatide administration have the benefit of ensuring adequate anatomical reduction. When used together, new fractures treated surgically with concomitant administration of teriparatide achieves significant radiological and clinical improvements. An isolated case study presented by Knecht (2004) demonstrated the benefits of teriparatide when used as an adjunct in the management of a tibial and fibula fracture (Knecht, 2004). The patient, a 47 year old man, was able to resume running 3 months after the fracture and achieved complete healing clinically and radiologically after 6 months. In a larger study, Tarantino *et al.* (2007) showed that in a group of 34 surgical patients (29 out of 34 were treated after sustaining a fracture) who received teriparatide immediate after intervention, majority benefited from shorter time to fracture healing (Tarantino *et al.*, 2007). The Visual Analogue Scale (VAS) which measured patient's perception of pain before and after treatment was noted to have decreased (Table 2).

Teriparatide also appears to have a role in the management of hypophosphatemic patients. These patients have defective bone mineralization, are highly susceptible to bony fractures and currently have no established medical therapy available. In 2 isolated case studies, institution of daily subcutaneous teriparatide (20 μ g day⁻¹) led to clinical improvements of pain alleviation, increased mobility and improved biochemical response (Whyte *et al.*, 2007; Gagnon *et al.*, 2010) (Table 2).

The short-term safety profile of teriparatide continues to be excellent with only 3.1% (8 out of 254) of patients experiencing mild side effects ranging from nausea, vomiting and headache. In the study by Peichl et al. (2011) no adverse events or death were recorded among the 21 patients who took PTH 1-84 for 24 months (Peichl et al., 2011). The long-term safety profile of teriparatide is however still unknown. The anabolic effects of teriparatide when given long-term and in supra-physiological doses were associated with increased risk of osteosarcomas in Fisher rats (Vahle et al., 2002). This risk is negated by the use of smaller doses in humans and is somewhat comparable to the general population risk, where only 1 case of osteosarcoma has been reported (Harper et al., 2007) among more than 250,000-300,000 patients treated with teriparatide worldwide (Solomon et al., 2009). However, in view of this theoretical adverse effect, use of teriparatide is cautioned in individuals with significant history of primary or metastatic bone tumours, Paget's disease, unexplained high levels of ALP, history of radiation therapy involving the bones or metabolic bone disease excluding osteoporosis, pregnancy and breast feeding (Guide et al., 2002). Of all the studies we analysed, there were no reports of any osteosarcomas developing as a result of teriparatide administration. Other side effects of teriparatide include dizziness, constipation, lethargy, muscle weakness and leg cramps secondary to raised serum calcium levels. Local side effects at injection site include erythema, swelling, itch and pain. Teriparatide usage also can

raise serum uric acid levels and has been cautioned in renal impaired patients (Miller *et al.*, 2007).

We acknowledge several limitations in our study. Considering the relative recent application of teriparatide in treating fracture healing, our results were limited by the small number of studies. In addition, 10 out of 12 of our studies were made up of case reports or series showing anecdotal evidences of the beneficial effects of teriparatide. The small sample size and the limited number of studies with higher level evidence in the literatures were limiting factors for our study. Also, there were some difficulties in the collection of data as studies were unclear regarding some patient demographics, time to fracture union of individual bones and teriparatide dosing regimen.

CONCLUSION

Teriparatide with its relatively safe drug profile continues to be a viable option for the treatment of fractures. Larger, well designed clinical trials should be conducted to evaluate (1) the optimal dosing regimen of teriparatide, (2) the patient type who would best benefit from teriparatide and (3) the type of fractures (delayed or non-union or new) that would respond best to teriparatide therapy. A prospective randomized controlled to compare conventional treatment against teriparatide therapy and against teriparatide plus conventional treatment with proper inclusion and exclusion criteria to account for potential confounding variables would be ideal in better understanding the clinical efficacy of teriparatide.

ACKNOWLEDGMENT

This research received no specific grant from any funding agency in the public, commercial or not-forprofit sector. All authors declare no conflict of interest.

REFERENCES

- Aspenberg, P., H.K. Genant, T. Johansson, A.J. Nino and K. See *et al.*, 2010. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J. Bone Mineral Res., 25: 404-414. DOI: 10.1359/jbmr.090731
- Brunnemann, C.E., E.C. Reisinger, D. Ganzer and H.C. Schober, 2010. Parathyroid hormone injection to counteract delayed bone fractures. Thieme J., 135: 1538-1541. DOI: 10.1055/s-0030-1262443

- Bukata, S.V. and J.E. Puzas, 2010. Orthopedic uses of teriparatide. Curr. Osteoporos Rep., 8: 28-33. DOI: 10.1007/s11914-010-0006-3
- Bukata, S.V., L.A. Kaback, D.G. Reynolds, R.J. Keefe and R.N. Rosier, 2009. 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: An observational cohort of 145 patients. Proceedings of the 55th Annual Meeting of the Orthopaedic Research Society, Feb. 22-25, Las Vegas.
- Canalis, E., A. Giustina and J.P. Bilezikian, 2007. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med., 357: 905-916.
- Chintamaneni, S., K. Finzel and B.L. Gruber, 2010. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporosis Int., 21: 1059-1063. DOI: 10.1007/s00198-009-1061-4
- Dempster, D.W., F. Cosman, E.S. Kurland, H. Zhou and J. Nieves *et al.*, 2001. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J. Bone Miner Res., 16: 1846-1853. DOI: 10.1359/jbmr.2001.16.10.1846
- Etoh, M. and A. Yamaguchi, 2010. Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone. J. Bone Miner. Metab., 28: 641-649. DOI: 10.1007/s00774-010-0181-4
- Gagnon, C., A.N. Sims, S. Mumm, S.A. McAulley and C. Jung *et al.*, 2010. Lack of Sustained Response to Teriparatide in a Patient with Adult Hypophosphatasia. J. Clin. Endocrinol. Metab., 95: 1007-1012. DOI: 10.1210/jc.2009-1965
- Gardner, M.J., J.B. Toro-Arbelaez, M. Harrison, C. Hierholzer and D.G. Lorich *et al.*, 2008. Open reduction and internal fixation of distal femoral nonunions: Long-term functional outcomes following a treatment protocol. J. Trauma, 64: 434-438. PMID: 18301211
- Gupta, A.K., M. Gupta, G. Sengar and R. Nath, 2012. Functional outcome of closed fractures of proximal humerus managed by Joshi's external stabilizing system. Indian J. Orthop., 46: 216-220. PMID: 22448062
- Harper, K.D., J.H. Krage, R. Marcus and B.H. Mitlak, 2007. Osteosarcoma and teriparatide? J. Bone Miner Res., 22: 334-334. DOI: 10.1359/jbmr.061111
- Heaney, R.P., 2003. Advances in therapy for osteoporosis. Clin. Med. Res., 1: 93-99. DOI: 10.3121/cmr.1.2.93

- Knecht, T.P., 2004. Teriparatide and fracture healing in cortical bone. Endocr Pract, 10: 293-293. PMID: 15382326
- Lindsaym, R., H. Zhou, F. Cosman, J. Nieves and D.W. Dempster *et al.*, 2007. Effects of a one-month treatment With PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone Miner Res., 22: 495-502. DOI: 10.1359/jbmr.070104
- Miller, P.D., J.P. Bilezikian, M. Diaz-Curiel, P. Chen and F. Marin *et al.*, 2007. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J. Clin. Endocrinol. Metab., 92: 3535-3541. DOI: 10.1210/jc.2006-2439
- Nakajima, A., N. Shimoji, K. Shiomi, S. Shimizu and H. Moriya *et al.*, 2002. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J. Bone Miner Res., 17: 2038-2047. DOI: 10.1359/jbmr.2002.17.11.2038
- Oteo-Alvaro, A. and E. Moreno, 2010. Atrophic humeral shaft nonunion treated with teriparatide (rh PTH 1-34): A case report. J. Shoulder Elbow Surg, 19: e22-e28. PMID: 20846618
- Paul, S.M., D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger and B.H. Munos, 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Dis. 9: 203-214 DOI:10.1038/nrd3078
- Peichl, P., L.A. Holzer, R. Maier and G. Holzer, 2011. Parathyroid hormone 1-84 accelerates fracturehealing in pubic bones of elderly osteoporotic women. J. Bone Joint Surg Am., 93: 1583-1587. DOI: 10.2106/JBJS.J.01379

- Resmini, G. and G. Iolascon, 2007. 79-year-old postmenopausal woman with humerus fracture during teriparatide treatment. Aging. Clin. Exp. Res., 19: 30-31. PMID: 18182890
- Rubery, P.T. and S.V. Bukata, 2010. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: A report of 3 cases. J Spinal Disord Tech., 23: 151-155. PMID: 20051918
- Ryder, K.M., S.B. Tanner, L. Carbone, J.E. Williams and H.M.Taylor *et al.*, 2010. Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J. Bone Miner. Metab., 28: 233-239. DOI: 10.1007/s00774-009-0123-1
- Solomon, D.H., L. Rekedal and S.M. Cadarette, 2009. Osteoporosis treatments and adverse events. Curr. Opin. Rheumatol., 21: 363-368. DOI: 10.1097/BOR.0b013e32832ca433
- Tarantino, U., G. Cannata, I. Cerocchi, D. Lecce and R. lundusi *et al.*, 2007. Surgical approach to fragility fractures: Problems and perspectives. Aging. Clin. Exp. Res., 19: 12-21. PMID: 18182887
- Vahle, J.L., M. Sato, G.G. Long, J.K. Young and P.C. Francis *et al.*, 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol., 30: 312-321. PMID: 12051548
- Verhaar, H.J. and W.F. Lems, 2009. PTH-analogs: Comparable or different? Arch Gerontol Geriatr, 49: e130-e132. DOI: 10.1016/j.archger.2008.11.004
- Whyte, M.P., S. Whyte and C. Deal, 2007. Adult hypophosphatasia treated with teriparatide. J. Clin. Endocrinol. Metab., 92: 1203-1208. DOI: 10.1210/jc.2006-1